Mumbai: Donald Trump has slapped a 100% pharma tariff on branded imports. He refers to it as “national security.” For India’s $10 billion pharma export machine, it’s a bitter pill.
Trump’s latest tariff tantrum
On Truth Social, his megaphone of choice, Trump declared that starting October 1, 2025, the USA will impose a 100% tariff on “any branded or patented Pharmaceutical Product” unless the company is building a factory in America.
And in true Trump fashion, the definition of “building” is malleable. Breaking ground, putting up a signboard, maybe even hiring a contractor, it all counts as “under construction.”
Generics are technically spared. But when has Trump ever stopped at the first punch?
Why India can’t ignore this
America is India’s biggest buyer of medicines. Of the $27.9 billion worth of drugs India exported in FY24, $8.7 billion, 31%, went to the USA Another $3.7 billion flowed in the first half of 2025.
India supplies 45% of generics and 15% of biosimilars used in the USA That’s nearly half of America’s cheap pill cabinet filled by Indian factories. If the White House keeps moving the goalposts, India’s pharma giants will feel the burn.
The Pharmaceuticals Export Promotion Council of India pegs USA-bound branded and patented products at roughly $10 billion. That’s the part of the pipeline now at risk.
Industry reaction: caution, not panic
Market response was muted but telling. AstraZeneca slipped 1.4%, Roche dropped 1%. In India, Sun Pharma sank 5% to a 52-week low.
Analysts are already parsing Trump’s “fine print”:
Maitri Sheth (Choice Institutional Equities): Generics are technically safe, but ambiguity remains around complex generics and specialty medicines.
Dr. VK Vijayakumar (Geojit Investments): Called it exactly what it is, another “tariff tantrum.” His point: generics are untouched, but Trump’s track record suggests the scope could widen.
Pankaj Pandey (ICICI Securities): Short-term impact limited. Long-term? Watch biosimilars.
Sunny Agarwal (SBI Securities): If Trump can hit branded drugs today, he can drag generics into the firing line tomorrow.
Investors aren’t blind. They’ve seen this movie before; Trump’s tariffs rarely stop at Act I.
Indian pharma’s vulnerability: company by company
Nomura and other brokerages have broken down just how exposed India’s top pharma players are:
- Dr. Reddy’s Laboratories (DRL): 47% of revenue from the USA, barely 15% of production inside America. High-risk.
- Sun Pharma: 37% of sales in the USA, 90% of specialty products made abroad. Its blockbuster Ilumya is produced in Ireland. Pain incoming.
- Cipla: 30% of revenues USA-linked. Its Invagen USA sites cover 25–30% of that. Rest depends on India.
- Aurobindo Pharma: $1.6B in USA sales. Three USA plants, but still limited output. Scaling up oral dosages could help.
- Zydus Lifesciences: ~$1.3B in USA sales, barely any American footprint. Red alert.
- Lupin: ~$1.1B in USA sales. Just 6–7% made domestically. Too thin to offset tariffs.
In short, most Indian majors are USA-dependent, thin on local production, and would bleed if Trump widens his net.
Trump vs treaties: déjà vu
It isn’t just about pharma. Trump is again testing global trade pacts.
The EU deal capped tariffs at 15% with a “no stacking” clause. Switzerland struck a 39% deal with pharma exemptions. Trump’s 100% bombshell appears to casually ignore both.
In other words, allies’ signatures are just wallpaper when Trump’s pen is in hand.
Beyond pharma: trucks and bathroom cabinets?
Trump’s tariff spree wasn’t limited to drugs. Heavy trucks imported into the USA: 25% duty. Cabinets and bathroom vanities? 50%. Upholstered furniture? 30%.
And the justification? National security.
Because clearly, nothing threatens America’s sovereignty like a bathroom cabinet from Vietnam.
India’s survival instincts: pivot already underway
Indian drugmakers aren’t blind to America’s mood swings. Diversification into Africa, Latin America, biosimilars, and innovation pipelines is already in motion.
Om Ghawalkar of Share Market calls this an “inflexion point.” Translation: build in America or hedge elsewhere. Either way, expect volatility.
The long-term play? Indian companies that invest in USA plants may actually end up more competitive, getting tariff-free access and political goodwill. But that requires massive capex and patience.
American consumers: the unintended casualties
Here’s the irony Trump won’t say out loud. If tariffs expand to generics, millions of American patients will be hit first.
- Indian generics save the USA healthcare billions every year.
- Tariffs = higher prices = fatter bills for insurers and patients.
- Shortages could follow, as Indian companies won’t subsidize thin-margin exports forever.
India may bleed revenues, but Americans will swallow the real inflation pill.
National pride, global pharmacy
India’s pharma sector is not just another export engine. It’s the pharmacy of the world. From HIV drugs in Africa to cancer therapies in the USA, Indian manufacturers are the silent backbone of global healthcare.
Trump’s stunt isn’t just about trade; it’s about dismantling a system where India keeps medicine affordable and accessible.
If Washington wants to pay triple for pills to flex “national security,” fine. But don’t expect India to apologise for running the most efficient pharma machine on the planet.
History lesson: Trump and tariff toys
We’ve seen this before. Steel, aluminum, China tariffs, the playbook hasn’t changed. Trump slaps a tax, investors panic, companies scramble, and eventually either:
- A deal gets cut.
- USA consumers pay higher costs.
- Both.
Pharma is different, though. It’s not steel or cabinets. This is about life-saving drugs. Treating medicine like another pawn on a tariff chessboard is reckless, even for Trump.
What happens next?
- Indian pharma: Braces for margin pressure, accelerates USA manufacturing.
- USA consumers: Face higher drug costs, potential shortages.
- Global trade: More friction at WTO, more bilateral headaches.
- Trump: Gets to thump his chest about “bringing jobs home.”
But like every tariff blitz, the short-term optics come at long-term cost.
The bigger pill to swallow
This isn’t an economic strategy, it’s economic theatre. India will adapt. Its pharma majors have the scale, cost base, and global demand to pivot. But Trump’s move once again exposes America’s double standard: preach “free trade,” practice protectionism.
